Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
CYCCP's Cash-to-Debt is ranked higher than
93% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. CYCCP: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CYCCP' s Cash-to-Debt Range Over the Past 10 Years
Min: 1  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.75
CYCCP's Equity-to-Asset is ranked higher than
63% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. CYCCP: 0.75 )
Ranked among companies with meaningful Equity-to-Asset only.
CYCCP' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.51  Med: 0.76 Max: 0.88
Current: 0.75
-3.51
0.88
Interest Coverage No Debt
CYCCP's Interest Coverage is ranked higher than
91% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYCCP: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CYCCP' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -19.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -1503.75
CYCCP's Operating Margin % is ranked lower than
81% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. CYCCP: -1503.75 )
Ranked among companies with meaningful Operating Margin % only.
CYCCP' s Operating Margin % Range Over the Past 10 Years
Min: -25222.48  Med: -4811.63 Max: -831.79
Current: -1503.75
-25222.48
-831.79
Net Margin % -1248.83
CYCCP's Net Margin % is ranked lower than
79% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. CYCCP: -1248.83 )
Ranked among companies with meaningful Net Margin % only.
CYCCP' s Net Margin % Range Over the Past 10 Years
Min: -19110.14  Med: -4605.02 Max: -737.76
Current: -1248.83
-19110.14
-737.76
ROE % -72.46
CYCCP's ROE % is ranked lower than
70% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. CYCCP: -72.46 )
Ranked among companies with meaningful ROE % only.
CYCCP' s ROE % Range Over the Past 10 Years
Min: -156.88  Med: -98.34 Max: -42.99
Current: -72.46
-156.88
-42.99
ROA % -53.68
CYCCP's ROA % is ranked lower than
66% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. CYCCP: -53.68 )
Ranked among companies with meaningful ROA % only.
CYCCP' s ROA % Range Over the Past 10 Years
Min: -86.17  Med: -58.95 Max: -34.56
Current: -53.68
-86.17
-34.56
ROC (Joel Greenblatt) % -9441.48
CYCCP's ROC (Joel Greenblatt) % is ranked lower than
85% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. CYCCP: -9441.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CYCCP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10207.43  Med: -3822.33 Max: -1007.24
Current: -9441.48
-10207.43
-1007.24
3-Year Revenue Growth Rate 92.80
CYCCP's 3-Year Revenue Growth Rate is ranked higher than
94% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. CYCCP: 92.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CYCCP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -23 Max: 92.8
Current: 92.8
0
92.8
3-Year EBITDA Growth Rate -35.40
CYCCP's 3-Year EBITDA Growth Rate is ranked lower than
84% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. CYCCP: -35.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CYCCP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -50.2  Med: -31.7 Max: 13.8
Current: -35.4
-50.2
13.8
3-Year EPS without NRI Growth Rate -36.40
CYCCP's 3-Year EPS without NRI Growth Rate is ranked lower than
81% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. CYCCP: -36.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CYCCP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -52.2  Med: -32.3 Max: 22.9
Current: -36.4
-52.2
22.9
GuruFocus has detected 1 Warning Sign with Cyclacel Pharmaceuticals Inc $CYCCP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CYCCP's 10-Y Financials

Financials (Next Earnings Date: 2017-03-24)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with CYCCP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Cyclacel Pharmaceuticals Inc

SymbolPriceYieldDescription
CYCCP6.374.716% Convertible Exchangeable Preferred Stock

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:GTHR, OTCPK:HSTC, OTCPK:GLAG, OTCPK:NTRR, OTCPK:NSPX, OTCPK:PTEO, OTCPK:ERGO, OTCPK:TLOG, OTCPK:ENTB, OTCPK:USRM, OTCPK:ICOTF, OTCPK:LCAR, OTCPK:ADYNF, OTCPK:CAPS, OTCPK:HDVY, OTCPK:FPMI, OTCPK:BTHE, OTCPK:BPSR, OTCPK:CTTC, OTCPK:GOVX » details
Traded in other countries:UXI3.Germany,
Cyclacel Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases.

Cyclacel Pharmaceuticals Inc was founded in August 13, 1996 and is incorporated in Delaware. The Company is a biopharmaceutical company engaged in the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. The Company develops and commercializes small-molecule drugs that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, particularly those of high unmet medical need. Its clinical development priorities are focused on sapacitabine only, its second drug candidate, seliciclib, is a novel, orally-available, CDK clinical development priorities are focused on sapacitabine as an orphan drug for the treatment of both Acute Myeloid Leukemia, or AML, and Myelodysplastic Syndromes, or MDS. The Company is currently evaluating sapacitabine in a Phase 3 study being conducted under a Special Protocol Assessment, or SPA, with the FDA for the front-line treatment of AML in the elderly. The Company is also exploring sapacitabine in Phase 2 studies for MDS, non-small cell lung cancer, or NSCLC, and chronic lymphocytic leukemia, or CLL and in a Phase 1 study in solid tumors in combination with seliciclib, another of its drug candidates. Sapacitabine has been evaluated in approximately 1,000 patients to date. In addition, in polo-like kinase, or PLK inhibitor program, the Company has discovered CYC140 and other small molecule inhibitors of PLK1, a kinase active during cell division, targeting the mitotic phase of the cell cycle. The Company retains all marketing rights for these compounds internationally.

Ratios

vs
industry
vs
history
PB Ratio 1.04
CYCCP's PB Ratio is ranked higher than
91% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. CYCCP: 1.04 )
Ranked among companies with meaningful PB Ratio only.
CYCCP' s PB Ratio Range Over the Past 10 Years
Min: 0.22  Med: 1.91 Max: 13.13
Current: 1.04
0.22
13.13
PS Ratio 12.36
CYCCP's PS Ratio is ranked higher than
55% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. CYCCP: 12.36 )
Ranked among companies with meaningful PS Ratio only.
CYCCP' s PS Ratio Range Over the Past 10 Years
Min: 5.02  Med: 64.6 Max: 9520
Current: 12.36
5.02
9520
Current Ratio 4.05
CYCCP's Current Ratio is ranked higher than
50% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. CYCCP: 4.05 )
Ranked among companies with meaningful Current Ratio only.
CYCCP' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 4.02 Max: 12.96
Current: 4.05
0.96
12.96
Quick Ratio 4.05
CYCCP's Quick Ratio is ranked higher than
53% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CYCCP: 4.05 )
Ranked among companies with meaningful Quick Ratio only.
CYCCP' s Quick Ratio Range Over the Past 10 Years
Min: 0.96  Med: 4.02 Max: 12.96
Current: 4.05
0.96
12.96
Days Sales Outstanding 742.20
CYCCP's Days Sales Outstanding is ranked lower than
99% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. CYCCP: 742.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYCCP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 568.15  Med: 777.81 Max: 6980.27
Current: 742.2
568.15
6980.27

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.71
CYCCP's Dividend Yield % is ranked lower than
99.99% of the 223 Companies
in the Global Biotechnology industry.

( Industry Median: 1.29 vs. CYCCP: 4.71 )
Ranked among companies with meaningful Dividend Yield % only.
CYCCP' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 161.75
Current: 4.71
0
161.75
Forward Dividend Yield % 9.41
CYCCP's Forward Dividend Yield % is ranked lower than
99.99% of the 208 Companies
in the Global Biotechnology industry.

( Industry Median: 1.22 vs. CYCCP: 9.41 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.71
CYCCP's 5-Year Yield-on-Cost % is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. CYCCP: 4.71 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
CYCCP' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 161.75
Current: 4.71
0
161.75
3-Year Average Share Buyback Ratio -60.40
CYCCP's 3-Year Average Share Buyback Ratio is ranked lower than
90% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. CYCCP: -60.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CYCCP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -144.5  Med: -43 Max: 0
Current: -60.4
-144.5
0

Valuation & Return

vs
industry
vs
history

More Statistics

Beta0.75
Short Percentage of Float0.04%
52-Week Range $4.21 - 55.20
» More Articles for CYCCP

Headlines

Articles On GuruFocus.com
Wilbur Ross Buys Two New Stakes in First Quarter Jun 15 2015 
Insider Cluster Buying Reported in Several Companies May 30 2013 
Cyclacel Pharmaceuticals Inc. Reports Operating Results (10-K/A) May 17 2010 
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 

More From Other Websites
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financial Results Mar 21 2017
Cyclacel’s CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of... Mar 07 2017
Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With... Feb 23 2017
Cyclacel Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference Feb 06 2017
Cyclacel's Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential in Esophageal Cancer and... Dec 01 2016
Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results Nov 14 2016
Cyclacel Pharmaceuticals to Release Third Quarter 2016 Financial Results Nov 07 2016
Cyclacel's CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data... Sep 06 2016
Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results Aug 10 2016
Cyclacel Pharmaceuticals to Release Second Quarter 2016 Financial Results Aug 03 2016
Cyclacel's CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data... Aug 02 2016
Cyclacel Regains Compliance With Nasdaq Continued Listing Requirements Jun 16 2016
Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine... Jun 06 2016
Cyclacel Announces Reverse Stock Split May 27 2016
Cyclacel's Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American... May 19 2016
Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results May 11 2016
Cyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results May 04 2016
Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in... Apr 18 2016
Cyclacel Announces Receipt of Nasdaq Extension Apr 11 2016
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results Mar 24 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)